Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 28

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 28
---
------:|:----|:----|-----:|
| First Quarter                         |     | $    | 10.89 |     | $   | 5.89 |
| Second Quarter                        |     |      |  7.16 |     |     | 1.25 |
| Third Quarter                         |     |      |  2.28 |     |     | 1.50 |
| Fourth Quarter                        |     |      |  2.00 |     |     | 1.46 |

As of November 10, 2025 there were approximately 481 holders of our Common Stock.

As of November 10, 2025 there were approximately 480 holders of our Series A Preferred Stock.

As of November 10, 2025 there was 1 holder of our Series AA Preferred Stock.

As of November 10, 2025 there were approximately 7 holders of our Series M Preferred Stock

As of November 10, 2025 there was one holder of our Series NC Preferred Stock.

Dividends

No cash dividends were paid during the fiscal year ending September 30, 2024 or on any date up to the date of this document. We do not expect to declare cash dividends in the immediate future.

Director Independence

Audit Committee and Audit Committee Financial Expert

The members of the Company’s board of Directors may not be considered independent. The Company is not a “listed company” under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company’s Board of Directors is deemed to be its audit committee and as such functions as an audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The Board of Directors has determined that its member is able to read and understand fundamental financial statements and has substantial business experience that results in that member’s financial sophistication. Accordingly, the Board of Directors believes that its member has the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit committee would have.

<div align='center'>21</div>

Nominating and Compensation Committees